Ardelyx

ARDX

Market cap $1.21B

WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, October 30, 2025, at 4:30 p.m.

WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the appointment of Sue Hohenleitner as Chief Financial Officer (CFO), effective November 4, 2025. Ms. Hohenleitner is a proven financial leader, bringing more than 30 years of experience in corporate finance, strategic planning, investor relations and operations across a variety of therapeutic areas and stages of development. She has a demonstrated track record of driving organizational transformation, building financial strength and driving sustainable growth across commercial and development-stage products. Ms. Hohenleitner most recently served as the Vice President and Chief Financial Officer of Johnson & Johnson (J&J) Innovative Medicine North America (NA), leading financial strategies for a $36 billion commercial business.

Ardelyx, Inc. (NASDAQ:ARDX ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 7:00 AM EDT Company Participants Michael Raab - President, CEO & Director Eric Foster - Chief Commercial Officer Justin Renz - Chief Financial & Operations Officer Conference Call Participants Robert Klingenberger Presentation Robert Klingenberger All right. Great. Good morning.

Ardelyx, Inc. (NASDAQ:ARDX ) Citi's Biopharma Back to School Conference September 3, 2025 1:00 PM EDT Company Participants Michael Raab - President, CEO & Director Eric Foster - Chief Commercial Officer Justin Renz - Chief Financial & Operations Officer Conference Call Participants Yigal Nochomovitz - Citigroup Inc., Research Division Presentation Yigal Nochomovitz Director and SMid Cap Biotech Analyst We're going to start the afternoon session. I'm Yigal Nochomovitz, biotech analyst at Citi.

WALTHAM, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced its participation in the following upcoming investor conferences: Citi Biopharma Back to School Summit Location: Boston, MAFireside Chat: Wednesday, September 3 at 1:00 p.m.

The share price of Ardelyx has finally broken the year-long downtrend after a strong second quarter earnings report. Ibsrela returned to stronger topline growth in Q2 and the company raised the full-year net sales guidance range for the product by $10 million at the mid-point. Xphozah is showing resilience post-Medicare access loss, with commercial sales stabilizing and the product seeing increased demand and sales growth in Q2 versus Q1.

Ardelyx Q2 Revenue Jumps 33%

Ardelyx, Inc. (NASDAQ:ARDX ) Q2 2025 Earnings Conference Call August 4, 2025 4:30 PM ET Company Participants Caitlin Lowie - Vice President of Corporate Communications & Investor Relations Eric Duane Foster - Chief Commercial Officer Justin A. Renz - Chief Financial & Operations Officer Michael G.

The headline numbers for Ardelyx (ARDX) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Ardelyx (ARDX) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.07 per share a year ago.